| Literature DB >> 35878224 |
Qian Chen1, Kai Zhang2, Mingjie Jiao1, Jiakang Jiao1, Dongling Chen1, Yihui Yin1, Jia Zhang1, Fei Li1.
Abstract
Mesaconitine (MA), one of the main diterpenoid alkaloids in Aconitum, has a variety of pharmacological effects, such as analgesia, anti-inflammation and relaxation of rat aorta. However, MA is a highly toxic ingredient. At present, studies on its toxicity are mainly focused on the heart and central nervous system, and there are few reports on the hepatotoxic mechanism of MA. Therefore, we evaluated the effects of MA administration on liver. SD rats were randomly divided into a normal saline (NS) group, a low-dose MA group (0.8 mg/kg/day) and a high-dose MA group (1.2 mg/kg/day). After 6 days of administration, the toxicity of MA on the liver was observed. Metabolomic and network toxicology methods were combined to explore the effect of MA on the liver of SD rats and the mechanism of hepatotoxicity in this study. Through metabonomics study, the differential metabolites of MA, such as L-phenylalanine, retinyl ester, L-proline and 5-hydroxyindole acetaldehyde, were obtained, which involved amino acid metabolism, vitamin metabolism, glucose metabolism and lipid metabolism. Based on network toxicological analysis, MA can affect HIF-1 signal pathway, MAPK signal pathway, PI3K-Akt signal pathway and FoxO signal pathway by regulating ALB, AKT1, CASP3, IL2 and other targets. Western blot results showed that protein expression of HMOX1, IL2 and caspase-3 in liver significantly increased after MA administration (p < 0.05). Combined with the results of metabonomics and network toxicology, it is suggested that MA may induce hepatotoxicity by activating oxidative stress, initiating inflammatory reaction and inducing apoptosis.Entities:
Keywords: apoptosis; hepatotoxicity; inflammatory response; mesaconitine; metabonomics; network toxicology; oxidative stress
Mesh:
Substances:
Year: 2022 PMID: 35878224 PMCID: PMC9322933 DOI: 10.3390/toxins14070486
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 5.075
Figure 1(A) The body weight of rats in the NS group and the MA group increased within 6 days. (B) Index of liver in NS group and MA group (compared with NS group: * p < 0.05). Results were analyzed by one-way ANOVA followed by a LSD test for multiple comparisons. (C) Serum ALT levels. The data were analyzed using a Kruskal–Wallis non-parametric test. (D) Serum AST levels. The data were analyzed using a Kruskal–Wallis non-parametric test. (E) Effects of MA on the morphology of liver in rats. NS group (E1,E2), low-dose group (E3,E4), high-dose group (E5,E6), red arrow points to hepatocyte necrosis or inflammatory cell infiltration.
Figure 2(A) PCA score plot for NS and MA groups. (A1: NS vs. low dose. A2: NS vs. high dose.). (B) OPLS-DA score plot for NS and MA groups. (B1: NS vs. low dose. B2: NS vs. high dose.). (C) Permutation test of OPLS-DA model. (C1: NS vs. low dose. C2: NS vs. high dose.). (D) S-plots obtained from OPLS-DA model. (D1: NS vs. low dose. D2: NS vs. high dose.). (E) Analysis of metabolic pathways. (E1: NS vs. low dose. E2: NS vs. high dose.).
Identification results of potential differential metabolites in rat serum.
| No. | Rt/min | Ion Mode | Obsed m/z | Calcd m/z | Error | Formula | Identify | HMDB | Group |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 0.931 | [M+H]+ | 130.08621 | 130.08625 | −0.307 | C6H11NO2 | D-Pipecolic acid | HMDB0005960 | High dose |
| 2 | 1.918 | [M+H]+ | 116.07054 | 116.07060 | −0.517 | C5H9NO2 | L-Proline | HMDB0000162 | Low dose |
| 3 | 2.217 | [M+H]+ | 132.10193 | 132.10190 | 0.227 | C6H13NO2 | D-Leucine | HMDB0013773 | High dose |
| 4 | 2.810 | [M+H]+ | 115.11172 | 115.11174 | −0.174 | C7H14O | 4-Heptanone | HMDB0004814 | High dose |
| 5 | 2.849 | [M+H]+ | 166.08612 | 166.08625 | −0.783 | C9H11NO2 | L-Phenylalanine | HMDB0000159 | Low dose |
| 6 | 3.373 | [M+H]+ | 340.10211 | 340.10269 | −1.705 | C15H17NO8 | 5-Hydroxy-6-methoxyindole glucuronide | HMDB0010363 | Low dose |
| 7 | 3.886 | [M+H]+ | 141.06564 | 141.06585 | −1.489 | C6H8N2O2 | Methylimidazoleacetic acid | HMDB0002820 | High dose |
| 8 | 4.757 | [M+H]+ | 514.28412 | 514.28329 | 1.614 | C26H43NO7S | Sulfolithocholylglycine | HMDB0002639 | Low dose |
| 9 | 4.901 | [M+H]+ | 176.07085 | 176.07060 | 1.420 | C10H9NO2 | 5-Hydroxyindoleacetaldehyde | HMDB0004073 | Low dose |
| 10 | 5.909 | [M+H]+ | 190.08615 | 190.08625 | −0.526 | C11H11NO2 | Indole-3-methyl acetate | HMDB0029738 | Low dose |
| 11 | 6.336 | [M+H]+ | 361.19955 | 361.20095 | −3.876 | C21H28O5 | Aldosterone | HMDB0000037 | Low dose |
| 12 | 7.945 | [M+H]+ | 466.31470 | 466.31631 | −3.453 | C26H43NO6 | Glycocholic acid | HMDB0000138 | Low dose |
| 13 | 8.033 | [M+H]+ | 289.21573 | 289.21620 | −1.625 | C19H28O2 | Dehydroepiandrosterone | HMDB0000077 | Low dose |
| 14 | 8.034 | [M+H]+ | 118.06486 | 118.06512 | −2.202 | C8H7N | Indole | HMDB0000738 | Low dose |
| 15 | 8.536 | [M+Na]+ | 351.23093 | 351.22945 | 4.214 | C22H32O2 | Docosahexaenoic acid | HMDB0002183 | Low dose |
| 16 | 8.823 | [M+K]+ | 369.24194 | 369.24016 | 4.821 | C19H38O4 | MG (0:0/16:0/0:0) | HMDB0011533 | Low dose |
| 17 | 9.351 | [M+H]+ | 314.23276 | 314.23258 | 0.573 | C17H31NO4 | 9-Decenoylcarnitine | HMDB0013205 | Low dose |
| 18 | 10.480 | [M+H]+ | 316.24741 | 316.24823 | −2.593 | C17H33NO4 | Decanoylcarnitine | HMDB0000651 | High dose |
| 19 | 12.718 | [M+H]+ | 368.27847 | 368.27953 | −2.878 | C21H37NO4 | 3,5-Tetradecadiencarnitine | HMDB0013331 | Low dose |
| 20 | 12.733 | [M+H]+ | 388.30527 | 388.30574 | −1.210 | C21H41NO5 | 2-Hydroxymyristoylcarnitine | HMDB0013166 | High dose |
| 21 | 12.750 | [M+H]+ | 295.22559 | 295.22677 | −3.997 | C18H30O3 | 9-OxoODE | HMDB0004669 | Low dose |
| 22 | 13.111 | [M+H]+ | 344.28049 | 344.27953 | 2.788 | C19H37NO4 | Dodecanoylcarnitine | HMDB0002250 | High dose |
| 23 | 14.109 | [M+H]+ | 303.23233 | 303.23185 | 1.583 | C20H30O2 | Retinyl ester | HMDB0003598 | Low dose |
| 24 | 18.521 | [M+H]+ | 422.32602 | 422.32648 | −1.089 | C25H43NO4 | Gamma-linolenyl carnitine | HMDB0006318 | Low dose High dose |
Analysis results of metabolic pathways related to differential metabolites.
| No. | Metabolic Pathway | Metabolite | p | −Log(p) | Holm p | FDR | Impact | Group |
|---|---|---|---|---|---|---|---|---|
| 1 | Phenylalanine, tyrosine and tryptophan | L-Phenylalanine | 0.031463 | 1.5022 | 1.0 | 1.0 | 0.5 | Low dose |
| 2 | Histidine metabolism | Methylimidazoleacetic acid | 0.041783 | 1.379 | 1.0 | 1.0 | 0.0 | High dow |
| 3 | Aminoacyl-tRNA biosynthesis | L-Phenylalanine; L-Proline | 0.05338 | 1.2726 | 1.0 | 1.0 | 0.0 | Low dose |
| 4 | Phenylalanine metabolism | L-Phenylalanine | 0.091683 | 1.0377 | 1.0 | 1.0 | 0.35714 | Low dose |
| 5 | Retinol metabolism | Retinyl ester | 0.12049 | 0.91906 | 1.0 | 1.0 | 0.16168 | Low dose |
| 6 | Steroid hormone biosynthesis | Dehydroepiandrosterone; Aldosterone | 0.12185 | 0.91416 | 1.0 | 1.0 | 0.0474 | Low dose |
| 7 | Pentose and glucuronate interconversions | beta-D-Glucuronoside | 0.13457 | 0.87104 | 1.0 | 1.0 | 0.14062 | Low dose |
| 8 | Biosynthesis of unsaturated fatty acids | (4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid | 0.25235 | 0.59799 | 1.0 | 1.0 | 0.0 | Low dose |
| 9 | Arginine and proline metabolism | L-Proline | 0.26449 | 0.57759 | 1.0 | 1.0 | 0.0778 | Low dose |
| 10 | Tryptophan metabolism | 5-Hydroxyindoleacetaldehyde | 0.28236 | 0.5492 | 1.0 | 1.0 | 0.02691 | Low dose |
| 11 | Primary bile acid biosynthesis | Glycocholic acid | 0.31125 | 0.50689 | 1.0 | 1.0 | 0.02285 | Low dose |
Figure 3Analysis results of network toxicology. (A) Venn diagram of 31 potential “common targets” was intersected by “component targets” and “hepatotoxicity targets”. (B) Protein–protein interaction (PPI) network. (C) Top 15 items of Go analysis. (C1: biological process. C2: cellular component. C3: molecular function.) (D) Enrichment analysis of KEGG pathways.
Figure 4The protein expressions of HMOX1 (A,B), IL2 (A,C), caspase-3 (A,D) in liver tissue were detected by Western blot. Compared with the NS group, * p < 0.05.
Administration scheme of MA.
| Grouping | Number | Drug | Dose | Method of Administration | Exposure Period |
|---|---|---|---|---|---|
| NS | 10 | 0.9% NaCl | 8.0 mL/kg/day | p.o., Continuous administration | 6 days |
| Low dose | 11 | MA | 0.8 mg/kg/day | p.o., Continuous administration | 6 days |
| High dose | 16 | MA | 1.2 mg/kg/day | p.o., Continuous administration | 6 days |